**Microbot Medical Regains Nasdaq Compliance on Minimum Bid Price Rule**

Microbot Medical Inc. has officially announced that it has received a notification letter from the Nasdaq Stock Market LLC, confirming that it has regained compliance with the minimum bid price requirement outlined in Nasdaq Listing Rule 5550(a)(2).

This decision by the Nasdaq staff comes after closely monitoring the minimum closing bid price of Microbot Medical’s common stock, which has traded at $1.00 per share or higher for 15 consecutive business days, commencing from December 26, 2024, to January 17, 2025.

Following this development, the Company is pleased to confirm its compliance with the Rule, and Nasdaq has concluded that the prior bid price deficiency matter is now resolved.

In response to these events, Microbot Medical filed the necessary Form 8-K with the Securities and Exchange Commission, indicating the successful regaining of compliance with the minimum bid price requirement.

Additionally, in accordance with Item 9.01 of the filing, Microbot Medical stated that no financial statements were required to be submitted, with the only exhibit being the Cover Page Interactive Data File embedded within the Inline XBRL document marked as Exhibit 104.

The filing was formally signed by Harel Gadot, the Chief Executive Officer, President, and Chairman of Microbot Medical Inc., on January 27, 2025, in compliance with the Securities Exchange Act of 1934.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Microbot Medical’s 8K filing here.

About Microbot Medical

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.